TG Therapeutics, Inc. (TGTX) Stock Overview
Explore TG Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
TG Therapeutics, Inc. (TGTX)
Key Financials
Key Financials
Market Cap
6.1B
P/E Ratio
12.69
EPS (TTM)
$2.86
ROE
0.87%
TGTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of TG Therapeutics, Inc. (TGTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 57.19, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $41.60.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 12.69 and a market capitalization of 6.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.